Second Medical Use

The analysis of Pro-Cure’s gene profile data has also shown cancer stem cells targets with so called “second medical use” opportunities. These are intracellular or extracellular proteins which are already targeted by existing, clinically validated therapeutic drugs.

These offer immediate partnering opportunities, provide insight relating to specific targeting pharmacophores and are near-market.
Join the Pro-Cure Team - Vacancies for Research Technicians: Validation of oncology targets in vitro (Job advertisement 24 February 2010)
The Company: Pro-Cure Therapeutics Limited is a young, innovative Bio...
Pro-Cure Therapeutics appoints Alastair Riddell as Chairman (Press Release 1 October 2009)
York, United Kingdom, 1 October 2009. Pro-Cure Therapeutics Ltd (P...
Pro-Cure Founder and CSO receives prestigious award for work in cancer research (Press Release 23 June 2009)
Professor Norman Maitland, founder and CSO of Pro-Cure Therapeutics Li...
UK Biotech companies join forces to develop novel prostate cancer vaccine (Press Release 14 May 2009)
York and Sheffield, United Kingdom. 14 May 2009. Pro-Cure Therapeut...
Cancer Research Company's £2 Million Boost (Press Release 27 January 2009)
A biotech company working on human cancer stem cells has secured a £2 ...